Abstract
Many live virus vaccines derived by empirical routes exhibit temperature-sensitive (ts) phenotypes. The live virus vaccines that have been outstandingly successful in controlling poliomyelitis are the prime example of this phenomenon. The three live attenuated strains developed by Albert Sabin were derived from wild-type isolates by rapid sequential passage at high multiplicity of infection (MOI) in monkey tissue in vitro and in vivo, a regimen that yielded variants of reduced neurovirulence. Concomitantly, the three vaccine strains developed ts characteristics, a phenotype that correlated well with loss of neurovirulence. The reproductive capacity at supraoptimal (40°C) temperature, the rct phenotype, proved to be a useful property for monitoring the genetic stability of the attenuated virus during propagation, vaccine production, and replication in vaccinees. Nucleotide sequencing of the genome of the poliovirus type 3 attenuated virus and its neurovirulent wild-type progenitor (the Leon strain), revealed that only ten nucleotide changes, producing three amino acid substitutions, differentiated the attenuated derivative from its virulent parent despite its lengthy propagation in cultured cells. One of the three coding changes, a serine-to-phenylalanine substitution at position 2034 in the region encoding VP3, conferred the ts phenotype. A combination of nucleotide sequencing of virus recovered from a vaccine-associated case of paralysis and assay in primates of the neurovirulence of recombinant viruses prepared from infectious cDNA established that two of the ten mutations in the type three vaccine strain were associated with the loss of neurovirulence.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Almond, J. W. (1987) The attenuation of poliovirus neurovirulence. Annu. Rev. Microbiol. 41, 153–180.
Murphy, B. R., Hall, S. L., Kulkarni, A. B., Crowe, Jr. J. E., Collins, P. L., Connors, M., et al. (1994) An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32, 13–36.
Garcia-Sastre, A. and Palese, P. (1993) Genetic manipulation of negative-strand RNA virus genomes. Annu. Rev. Microbiol. 47, 765–790.
Schnell, M. J., Mebatsoin T., and Conzelmann, K-K. (1994) Infectious rabies viruses from cloned cDNA. EMBO J. 13, 4195–4203.
Roner, M. R. and Joklik, W. K. (2001) Reovirus reverse genetics: Incorporation of the CAT gene into the reovirus genome. Proc. Natl. Acad. Sci. USA 98, 8036–8041.
Crowe, Jr., J. E. (1995) Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine 13, 415–421.
Juhasz, K., Whitehead S. S., Bui, P. T,, Biggs, J. M., Boulanger, C. A., Collins, P. L., et al. (1997) The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts53O, results from a single amino acid substitution in the L protein. J. Virol. 71, 5814–5819.
Crowe, J. E., Bui, P. T., Silber, G. R., Elkins, W. R., Chanock, R. M., and Murphy, B. R. (1995) Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even where RSV antibodies are infused shortly before immunization. Vaccine 13, 847–855.
Caplen, H., Peter, C. J., and Bishop, D. H. L. (1985) Mutagen-directed attenuation of Rift valley fever virus as a method for vaccine development. J. Gen. Virol. 66, 2271–2277.
McKay, E., Higgins, P., Tyrrell, D., and Pringle, C. R. (1988) Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers. J. Med. Virol. 25, 411–421.
Pringle, C. R., Filipiuk, A. H., Robinson, B. S., Watt, P. J., Higgins, P., and Tyrrell, D. A. J. (1993) Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11, 473–478.
Knight, V. (1964) The use of volunteers in medical virology. Prog. Med. Virol. 6, 1–26.
Gwaltney, Jr., J. M., Hendley, O., Hayden, F. G., McIntosh, K., Hollinger, F. B, Melnick, J. L., et al. (1994) Updated recommendations for safety-testing of viral inocula used in volunteer experiments on rhinovirus colds. Prog. Med. Virol. 39, 256–263.
Gimenez, H. B. and Pringle, C. R. (1978) Seven complementation groups of respiratory syncytial virus temperature-sensitive mutants. J. Virol. 27, 459–464.
Ling, R. and Pringle, C. R. (1988) Turkey rhinotracheitis virus: in vivo and in vitro polypeptide synthesis. J. Gen. Virol. 69, 917–923.
Leppard, K. N. and Pringle, C. R. (1996) Virus Mutants, in Virology Methods Manual (Kangro, H. and Mahy, B. W. J., eds.), 11, 231–248, Academic Press Ltd., London.
Pringle, C. R. (1985) Pneumoviruses, in Virology; A Practical Approach (Mahy, B. W. J., ed.), pp. 95–118, IRL Press, Oxford, and Washington, D.C.
Tolley, K. P., Marriott, A. C., Simpson, A., Plows, D. J., Matthews, D. A., Longhurst, S. J., et al. (1996) Identification of mutations contributing to the reduced virulence of a modified strain of respiratory syncytial virus. Vaccine 14, 1637–1646.
Pringle, C. R. (1990) The Genetics of Viruses, in Topley and Wilson’s Principles of Bacteriology, Virology and Immunity, 7th ed., Vol. 4 (Collier, L. H. and Timbury, M. C., eds.), Edward Arnold, London, Melbourne, and Auckland, pp. 69–104.
Watt, P. J., Robinson, B. S., Pringle, C. R., and Tyrrell, D. A. J. (1990) Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 8, 231–236.
Murphy, B. R. (1993) Use of lived attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults and elderly adults. Infect. Dis. Clin. Pract. 2, 176–181.
Partin, N. T., Chiu, P., and Coelingh, K. (1997) Genetically engineered live attenuated Influenza A vaccine candidates. J. Virol. 71, 2772–2778.
Whitehead, S. S., Firestone, C-Y., Karron, R. A., Crowe, J. E., Elkins, W. R., Collins, P. L., et al. (1999). Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J. Virol. 73, 871–877.
Bin, R. B., Ma, C-H., Kristoff, T., Cheng, X., and Jin, H. (2002) Identification of temperature sensitive mutations in the phosphoprotein of respiratory syncytial virus that are likely involved in its interaction with the nucleoprotein. J. Virol. 76, 2871–2880.
Marriott, A. C. and Easton, A. J. (1999) Reverse genetics of the Paramyxoviridae. Adv. Virus Res. 53, 321–340.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Pringle, C.R. (2003). Temperature-Sensitive Mutant Vaccines. In: Robinson, A., Hudson, M.J., Cranage, M.P. (eds) Vaccine Protocols. Methods in Molecular Medicine™, vol 87. Humana Press. https://doi.org/10.1385/1-59259-399-2:19
Download citation
DOI: https://doi.org/10.1385/1-59259-399-2:19
Publisher Name: Humana Press
Print ISBN: 978-1-58829-140-0
Online ISBN: 978-1-59259-399-6
eBook Packages: Springer Protocols